Vascular Biogenics Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Dror Harats
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 8 HaSatat Street Hevel Modi'in Israel 7178106
- IPO Date
- Oct 1, 2014
- CIK
- 0001603207
- Website
- vblrx.com
- Similar Companies
- Business
- Vascular Biogenics Ltd. (NASDAQ: VBLT), operating as VBL Therapeutics, is a clinical-stage biopharmaceutical company that develops targeted therapies for immune-inflammatory diseases and, previously, cancer. The company offers VB-601, a lead immunology product candidate utilizing proprietary monocyte targeting technology (MTT) designed to limit chronic inflammation and applicable to prevalent and rare inflammatory indications including multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease; it formerly advanced oncology programs such as VB-111, a targeted anti-cancer gene-therapy agent for solid tumors. Incorporated in 2000 and headquartered in Modi'in, Israel, with operations in Israel and the United States, VBL Therapeutics targets patients with high unmet needs in immune-inflammatory and oncology segments. In October 2023, the company completed a merger with Notable Labs, Inc., a precision oncology platform developer, forming Notable Labs Ltd. (NASDAQ: NTBL), with Notable stockholders owning approximately 76% and former VBLT shareholders 24% of the combined entity on a fully-diluted basis; the merged company advanced Notable's Predictive Precision Medicines Platform (PPMP) and lead asset Volasertib, a PLK1 inhibitor for acute myeloid leukemia in platform-predicted responders, supported by a concurrent $10.3 million private placement from investors including Builders VC, B Capital Group, Y Combinator, First Round Capital, and Founders Fund to fund operations into 2025. Prior to the merger, VBL Therapeutics sold its manufacturing facility and related assets in Modi'in, Israel, to Aleph Farms for $7.1 million in early 2023 to bolster cash reserves and shareholder value. The combined Notable Labs Ltd. ceased operations following a voluntary Chapter 7 bankruptcy filing on October 13, 2024, marking the end of ambitions for its cancer drug pipeline. VBLT shares reflect the delisted status of the predecessor entity post-merger and liquidation.
Amalgamated Bank Reduces Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)
Notable Labs Closes Merger Transaction With VBL Therapeutics
VBL Therapeutics Announces Results of Annual and Special Shareholder Meeting
VBL Therapeutics Reminds Shareholders to Vote in the Upcoming Annual and Special Shareholder Meeting
VBL Therapeutics Announces that S-4 Registration Statement for Proposed Merger with Notable Labs Is Declared Effective by SEC
VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT
VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
Best Penny Stocks to Buy Under $1? 10 To Watch Now
Penny Stocks To Buy? 10 Under $1 To Watch This Week
Penny Stocks To Buy? 7 Under $1 To Watch This Week
10 Penny Stocks Under $1 To Watch Now, Time To Buy?
7 Penny Stocks Under $1 To Watch Now, Time To Buy?
Penny Stocks To Buy: 5 To Watch Before Next Week
Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership
4 Penny Stocks Under $1 To Watch Now, Time To Buy?
VASCULAR BIOGENICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Vascular Biogenics Ltd. - VBLT
Maximizing Returns With Penny Stocks: Day Trading
Why Is Vascular Biogenics (VBLT) Stock Up 52%?
3 Top Penny Stocks To Watch With Big News Today
VBLT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Vascular Biogenics Ltd. Is Fair to Shareholders